PDS Biotechnology Corp (PDSB): Entry into a Material Definitive Agreement
PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ef20076071_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 PDS BIOTECHNOLOGY CORPORATION Common Stock (par value $0.00033 per share) Sales Agreement June 15, 2026 Yorkville Securities, LLC 1012 Springfield Avenue Mountainside, NJ 07092 B. Riley Securities, Inc. 299 Park Avenue, 21 st
How this was made
The 30-second read
Why it matters
The disclosed $50M aggregate offering price creates potential share supply; traders may reprice the stock for dilution risk until specific sales (if any) are executed and priced.
Market read
A newly disclosed registered equity sales agreement ($50M) is a direct capital-structure event that can drive trading via dilution expectations.
What to watch
The agreement’s impact depends on actual sales pace, any concurrent financing/clinical milestones, and whether pricing is at a discount to market or structured to minimize dilution.
Background
The SEC 8-K reports entry into a material definitive agreement for an equity sales program under a Form S-3 registration statement and prospectus supplement framework.
Ticker impact
PDS Biotechnology entered a material definitive sales agreement to issue and sell up to $50M of common stock via agents.
Bias toward downside/volatility around execution and any subsequent drawdowns; magnitude depends on how quickly shares are sold.
A forward equity issuance program typically adds overhang risk, and the article provides the key parameter (aggregate offering price $50M) but not the timing or pricing of any specific tranche.
Market effects
Biotech issuers may face similar dilution overhang dynamics when using at-the-market/registered sales agreements.
No clear regional spillover indicated beyond US small/mid-cap biotech financing sentiment.
Limited; this is company-specific capital markets activity.
Counterpoint
If the company uses proceeds to fund near-term catalysts (trials, partnering, or runway extension), the facility can be viewed as balance-sheet optionality rather than immediate dilution.
Key entities
- issuerPDS Biotechnology Corporation
Company entering the sales agreement for issuance and sale of common stock.
- agentYorkville Securities, LLC
Agent under the sales agreement for placement of shares.
- agentB. Riley Securities, Inc.
Agent under the sales agreement; also referenced as qualified independent underwriter.
